EndoQuest plans to test its technology on an estimated 50 participants enrolled across five sites in the US. The company’s ...

FemPulse™ announced today Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin its EVANESCE II pivotal clinical trial in female patients suffering ...

FemPulse announced today that it received FDA investigational device exemption (IDE) approval for its overactive bladder (OAB ...

Artivion, Inc. announced that the FDA has granted a humanitarian device exemption (HDE) for use of the of the AMDS hybrid ...

EndoQuest will commence its PARADIGM clinical trial for endoluminal robotic colorectal surgery at five leading US hospitals ...

EndoQuest Robotics announced today that it received FDA investigational device exemption (IDE) for a study of its surgical ...

RapidPulse, Inc. announced FDA approval of an investigational device exemption (IDE) for the company to study the RapidPulse c ...

Theradaptive earned the FDA's investigational device exemption approval to broaden its clinical research for the OsteoAdapt SP implant, the company said Dec. 10 ...

Dividend Aristocrats offer stability, reliable income, and risk mitigation, with consistent dividend growth helping to combat ...

has submitted an Investigational Device Exemption (IDE) application for its pivotal colorectal clinical study. EndoQuest’s mission is to transform surgical outcomes for minimally invasive ...

has submitted an Investigational Device Exemption (IDE) application for its pivotal colorectal clinical study. EndoQuest’s mission is to transform surgical outcomes for minimally invasive ...